The great problems are in the street : a phenomenology of men's stranger intrusions on women in public spaces

This thesis contributes new and unique evidence to the limited body of empirical literature on men’s stranger intrusion in public space, commonly termed ‘street harassment’, through a transdisciplinary study bringing a philosophical framework to the study of violence against women and girls (VAWG). Analysis of 50 women’s accounts given during a three stage research process is presented, alongside the development of a theoretical framework combining feminist approaches to VAWG with the gendered existential-phenomenology of Simone de Beauvoir and insights on habitual embodiments from Maurice Merleau-Ponty. Using this theoretical framework the empirical evidence is investigated for what it reveals about modalities of embodied subjectivity women enact in public spaces. The research had four central aims and it is the achievement of these aims that forms the unique contribution of this thesis. Firstly it develops the reciprocal practice of translating philosophy into the vernacular of women’s experiences of VAWG, finding that a philosophical perspective assists a feminist reframing of medical/legal models of VAWG. Secondly it explores reconnecting feminist research on VAWG to women’s ordinary experience of men’s intrusion, revealing how the necessary focus on policy has led to a steep rise in knowledge about some forms of VAWG to the detriment of investigating men’s violence and intrusion in women’s everyday lives. The third aim, to understand the consequences of men’s intrusion for how women live and experience their bodily-self, resulted in a theoretical framework which suggests possibilities in the work of Simone de Beauvoir for feminists looking to reconnect questions of women’s agency and autonomy to a context of structural power relations. Finally this research produced a new body of evidence regarding the practice and experience of men’s stranger intrusion in public spaces, through a research process which created new tools for researching the ordinary. In the pursuit of these four aims this research found that, far from the trivialisation it is often afforded, the possibility and reality of men’s intrusion forms a fundamental factor in how women understand and enact their embodied selfhood

Sexual violence as a sexual script in mainstream online pornography

This article examines the ways in which mainstream pornography positions sexual violence as a normative sexual script by analysing the video titles found on the landing pages of the three most popular pornography websites in the United Kingdom. The study draws on the largest research sample of online pornographic content to date and is unique in its focus on the content immediately advertised to a new user. We found that one in eight titles shown to first-time users on the first page of mainstream porn sites describe sexual activity that constitutes sexual violence. Our findings raise serious questions about the extent of criminal material easily and freely available on mainstream pornography websites and the efficacy of current regulatory mechanisms

From ‘no means no’ to ‘an enthusiastic yes’: Changing the Discourse on Sexual Consent Through Sex and Relationships Education

How sexual consent should be discussed with young people is the subject of current policy debates and contestations in the UK. While the current Westminster government violence against women and girls (VAWG) strategy (Home Office, 2011) and subsequent action plans recognise the importance of addressing consent, with no statutory relationships and sex education there are few contexts in which these conversations with young people routinely take place. Organisations that work with young people as victims/survivors of violence and through school-based primary prevention programmes have long identified sexual consent as an issue which requires specialist attention and intervention (see e.g. Coy et al., 2010; EVAW, 2011)

Reasons rape investigations are closed by police

Briefing 3 of Pillar Five for Operation Soteria Bluestone. This briefing shares the results of research investigating why police in England and Wales close rape cases. It is part of the large-scale, UK Government funded Operation Soteria Bluestone which aims to improve police investigations of rape and other sexual offences. It is part of the large-scale, UK Government funded Operation Soteria Bluestone which aims to improve police investigations of rape and other sexual offences

Recording, reporting, and charge rates for rape in England and Wales

Briefing 2 of Pillar Five for Operation Soteria Bluestone. This briefing shares the results of research investigating the real scale and nature of rape reporting to and recording by the police, as well as the charge rate, in England and Wales. It is part of the large-scale, UK Government funded Operation Soteria Bluestone which aims to improve police investigations of rape and other sexual offences

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead